🇧🇷 Brazil Market Entry 📋 ANVISA Regulatory 📈 Real Search Data

Bringing a Supplement or Health Product to Brazil? Here’s What Actually Gets You Found.

Regulatory approval gets you on the shelf. Structured content and search visibility gets you found by the consumer who’s already searching for you.
💬 Talk to a Licensed Brazilian Pharmacist
Wagner Fernandes
Wagner Fernandes · CRF-RO 4509Licensed Pharmacist · Founder, FarmaCerto

The regulatory path is well documented. The visibility problem isn’t.

Several firms specialize in ANVISA registration for supplements and health products entering Brazil, covering RDC 243/2018 notification requirements, ingredient approval, labeling compliance, and local representation. That part of the process is solvable with the right regulatory partner.

What most brands underestimate is what happens after approval: Brazilian consumers research extensively online before buying a new supplement brand, and most of that research happens in Portuguese, on Google, often surfaced by AI search tools that increasingly cite structured, credentialed content over generic marketing pages.

📊 Real Platform Data

What we’ve built, and why it matters for your brand

FarmaCerto is a health content platform built from scratch by a licensed Brazilian pharmacist, generating real organic search traffic across hundreds of published pages covering medications, supplements, and treatment information Brazilian consumers actually search for.

~500
Pages indexed
6 months
Organic growth, no paid ads
📊 Real Regulatory Data

The compliance gap most brands underestimate

According to ANVISA’s own public statements to the Brazilian Congress, 65% of new supplement products evaluated through July 2025 were rejected or flagged for irregularities, most commonly missing stability studies, incompatible dosages, or non-compliant labeling claims. This isn’t a niche problem. It’s the majority outcome for products entering the market without proper pre-market review.

What entering the Brazilian market actually requires

1

Regulatory classification

Determine whether your product qualifies as a dietary supplement (notification pathway) or requires full pharmaceutical registration, per RDC 243/2018 and RDC 373/2025.

2

Local representation

Foreign companies must designate a legally registered representative in Brazil, responsible for importation, distribution, and post-market surveillance.

3

Portuguese-language labeling and claims compliance

No therapeutic claims are allowed for supplements. Labeling must follow ANVISA guidelines precisely to avoid reclassification.

4

Search visibility and consumer trust

This is where most brands fall short. Being approved doesn’t mean being found. Structured, pharmacist-reviewed content is what Brazilian consumers, and AI search tools, actually trust.

What we bring to the table

✓ A licensed pharmacist (CRF-RO 4509) who understands both regulatory context and real consumer behavior in Brazil
✓ An existing content platform with real organic search traffic, not a page built from scratch for your brand alone
✓ Structured content (schema markup, cited sources) already recognized by Google and AI search as trustworthy
✓ Where regulatory expertise is needed beyond our scope, we can coordinate with trusted local partners
💬 Start the Conversation

✅ Credentials

✓ CRF-RO 4509, active pharmacist license
✓ Founder, FarmaCerto content platform
✓ Real organic search presence in Brazil
✓ Based in Brazil, working with the local market daily

Frequently Asked Questions

Most standard dietary supplements follow a notification pathway under RDC 243/2018, not full registration. High-risk or novel ingredients may require additional review. A locally registered company must be designated as the responsible party.
No. Supplements cannot claim to treat, cure, or prevent disease. Such claims may trigger reclassification as a pharmaceutical product, requiring a much more complex registration pathway.
A legally registered local representative in Brazil responsible for importation, distribution, and post-market surveillance, plus Portuguese-language labeling compliant with ANVISA guidelines.
According to ANVISA’s public data, the most common reasons are missing stability studies, dosages incompatible with Brazilian regulations, and label claims not permitted for the supplement category. Most of these issues are avoidable with proper pre-market review of formula and labeling before submission.
Regulatory approval alone doesn’t create demand. Brazilian consumers search extensively for product information, ingredient safety, and trusted reviews before purchasing. Structured, pharmacist-reviewed content already trusted by Google and AI search tools helps a brand be found at the exact moment consumers are deciding.

References: ANVISA RDC 243/2018 (dietary supplement notification). ANVISA RDC 373/2025 (updated ingredient and labeling rules). ANVISA statement to Brazilian Chamber of Deputies, Sept. 2025 (65% rejection rate data). Mavenrs, “ANVISA Nutraceutical Regulations Brazil 2025.”

Follow for more on Brazilian pharma market insights.